Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 4;2(1):59-67.
doi: 10.1016/j.xkme.2019.09.007. eCollection 2020 Jan-Feb.

Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation

Chiaki Kawabata  1 , Hirotaka Komaba  1   2 , Hiroaki Ishida  3 , Yosuke Nakagawa  1 , Naoto Hamano  1 , Masahiro Koizumi  1 , Genta Kanai  1 , Takehiko Wada  1 , Michio Nakamura  3 , Masafumi Fukagawa  1
Affiliations

Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation

Chiaki Kawabata et al. Kidney Med. .

Abstract

Rationale & objective: Patients with chronic kidney failure have markedly elevated fibroblast growth factor 23 (FGF-23) levels and decreased soluble Klotho levels. However, no studies have examined the effects of hemodialysis initiation on the levels of these hormones and other parameters of mineral metabolism.

Study design: Prospective single-arm study.

Setting & participants: 20 individuals with incident kidney failure initiating hemodialysis.

Exposure: Initiation of hemodialysis. Dose adjustments of phosphate binders and vitamin D receptor activators and use of calcimimetics, erythropoiesis-stimulating agents, and intravenous iron were prohibited.

Outcomes: Changes in serum levels of FGF-23, soluble Klotho, and other biochemical parameters of mineral metabolism, measured before and after each hemodialysis session, for a total of 4 sessions over 5 days.

Analytical approach: Repeated-measures analysis of variance.

Results: At baseline, participants had 18-fold higher median FGF-23 levels and 1.6-fold lower mean soluble Klotho levels compared with age- and sex-matched healthy individuals. Initiation of hemodialysis led to progressive reductions in serum phosphorus, intact parathyroid hormone, and FGF-23 levels, with dialysis-related fluctuations. No reductions were observed in levels of α1-microglobulin, which has molecular weight comparable to FGF-23. The magnitude of the FGF-23 level reductions was strongly associated with concomitant changes in serum phosphorus levels but not with the changes in intact parathyroid hormone levels. Soluble Klotho levels did not change after the initiation of hemodialysis.

Limitations: Single-arm design, small sample size, short follow-up period.

Conclusions: Initiation of hemodialysis in patients with chronic kidney failure led to progressive reductions in FGF-23 levels in association with reductions in serum phosphorus levels. These results suggest that phosphorus is a strong inducer of FGF-23 production and that regulation of FGF-23 production is a rapid process.

Keywords: Chronic kidney failure; FGF23; Klotho; hemodialysis; hyperphosphatemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in (A) serum creatinine, (B) calcium, (C) phosphorus, and (D) intact parathyroid hormone (PTH) levels after initiation of hemodialysis. Closed circles indicate predialysis values, and open circles indicate postdialysis values. Data for intact PTH were analyzed on the log scale and back-transformed for presentation. Abbreviation: CI, confidence interval. *P < 0.05 versus baseline.
Figure 2
Figure 2
Changes in (A) fibroblast growth factor 23 (FGF-23), (B) soluble Klotho, and (C) α1-microglobulin (A1M) levels after initiation of hemodialysis. Closed circles indicate predialysis values, and open circles indicate postdialysis values. Data for FGF-23 were analyzed on the log scale and back-transformed for presentation. Abbreviation: CI, confidence interval. *P < 0.05 versus baseline.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shimada T., Mizutani S., Muto T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500–6505. - PMC - PubMed
    1. Shimada T., Kakitani M., Yamazaki Y. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–568. - PMC - PubMed
    1. Larsson T., Marsell R., Schipani E. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145(7):3087–3094. - PubMed
    1. Kuro-o M., Matsumura Y., Aizawa H. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51. - PubMed
    1. Urakawa I., Yamazaki Y., Shimada T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770–774. - PubMed

LinkOut - more resources